Pregnancy

SURVEY SAYS: WHAT ONE-THIRD OF FIRST-TIME PARENTS WISHED THEY DID (OR KNEW) WHEN BRINGING BABY HOME

Research Shows First-Time Parents 'Longed for More' in Reflecting on Who they Wish They Were DOVER, Del., Nov. 12, 2024…

1 year ago

ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have been awarded The Galien Foundation 2024 Prix…

1 year ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS…

1 year ago

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for…

1 year ago

Curio Digital Therapeutics Applauded by Frost & Sullivan for Enhancing Women’s Maternal Mental Healthcare with its MamaLift and MamaLift Plus Solutions

MamaLift ensures personalized care tailored to each woman's journey through motherhood, empowering them to manage stress, embrace joy, and reduce…

1 year ago

Legacy and Posterity Health Announce Innovative Partnership to Increase Access to Male Fertility Care

NEW YORK, Oct. 18, 2024 /PRNewswire/ -- Legacy, the country's leading sperm testing and freezing company, and Posterity Health, the…

1 year ago

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT TrialSAN DIEGO, Oct.…

1 year ago